• Hongxia Chen, Xiaoyan Qiu, Jingyi Wang, and Hualing Wei.
• Department of pharmacy, Fudan University Huashan Hospital, Shanghai, China.
• Medicine (Baltimore). 2022 Dec 16; 101 (50): e31997e31997.

RationaleVarious side effects of interferon alfa-2b (IFN-α2b) have been reported. However, no relevant research has been conducted on the identification and treatment scheme selection for IFN-α2b induced severe systemic lupus erythematosus (SLE).Patient ConcernsA 41-years-old man with a long history of hepatitis B who developed severe active SLE after IFN-α2b therapy for 24 months, with complete and persistent remission of clinical and laboratory abnormalities after IFN-α2b withdrawal, was not observed.DiagnosisThe patient was diagnosed with interferon-associated lupus by a multidisciplinary team involving pharmacists, and lupus nephritis by renal biopsy.InterventionsMethylprednisolone (40 mg/day) with intravenous cyclophosphamide (600 mg/body weight) was initiated and the symptoms were partially relieved. Cyclophosphamide was increased from 600 mg to 850 mg at the pharmacist's recommendation.OutcomesThe patient showed a favorable response to these therapies.LessonsClinical pharmacists collaborated with other members of the health care team to diagnose and treat adverse reactions, resulting in improved patient management.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

27 keywords...

hide…